Aldeyra shares spiral after a late-stage failure in dry eye disease — but that won't stop its pursuit of an NDA

Nicole DeFeudis

Editor

Aldeyra Therapeutics’ shares tanked in premarket trading after the company admitted its dry eye candidate reproxalap missed the primary endpoint in a topline Phase III …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aldeyra shares spiral after a late-stage failure in dry eye disease — but that won't stop its pursuit of an NDA

Nicole DeFeudis

Editor

Sign up to read this article for free.

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Novartis turns to BioAge for new targets based on longevity and exercise

Exclusive: Color Health alums raise $10M for new startup, using AI for regulatory work

Aldeyra shares spi­ral af­ter a late-stage fail­ure in dry eye dis­ease — but that won't stop its pur­suit of an NDA

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

Aldeyra shares spiral after a late-stage failure in dry eye disease — but that won't stop its pursuit of an NDA

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Roche’s Parkinson’s drug flunks second mid-stage trial

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Novartis turns to BioAge for new targets based on longevity and exercise

Exclusive: Color Health alums raise $10M for new startup, using AI for regulatory work